Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNotes PayablesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Regen BioPharma (RGBP) Total Current Liabilities (2016 - 2025)

Regen BioPharma (RGBP) has disclosed Total Current Liabilities for 12 consecutive years, with $6.8 million as the latest value for Q4 2025.

  • On a quarterly basis, Total Current Liabilities rose 16.01% to $6.8 million in Q4 2025 year-over-year; TTM through Dec 2025 was $6.8 million, a 16.01% increase, with the full-year FY2025 number at $6.6 million, up 21.89% from a year prior.
  • Total Current Liabilities was $6.8 million for Q4 2025 at Regen BioPharma, up from $6.6 million in the prior quarter.
  • In the past five years, Total Current Liabilities ranged from a high of $77.4 million in Q1 2022 to a low of $5.2 million in Q1 2024.
  • A 5-year average of $10.6 million and a median of $5.9 million in 2024 define the central range for Total Current Liabilities.
  • Peak YoY movement for Total Current Liabilities: surged 1374.27% in 2022, then tumbled 93.1% in 2023.
  • Regen BioPharma's Total Current Liabilities stood at $10.5 million in 2021, then plummeted by 49.49% to $5.3 million in 2022, then fell by 0.98% to $5.2 million in 2023, then rose by 11.88% to $5.9 million in 2024, then rose by 16.01% to $6.8 million in 2025.
  • Per Business Quant, the three most recent readings for RGBP's Total Current Liabilities are $6.8 million (Q4 2025), $6.6 million (Q3 2025), and $6.0 million (Q2 2025).